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ABSTRACT
The sticky platelet syndrome (SPS) is a congenital disorder characterized by platelet hyperaggregability to 
epinephrine and/or adenosine diphosphate; this predisposes affected individuals to acute myocardial infarction, 
ischemic optic neuropathy, recurrent venous thromboembolism, and transient ischemic cerebral attacks and 
strokes. Here, we describe an unusual case with recurrent cerebrovascular accidents due to SPS, in the presence 
of a patent foramen ovale (PFO). We report an unusual case of a 56-year-old female patient with a PFO, who 
suffered from recurrent strokes despite long-term medication with clopidogrel for SPS. The patient underwent 
successful transcatheter closure of the PFO, and, in addition, she has been placed on low-dose acetylsalicylic 
acid. After 18-month follow-up, she demonstrated an intact atrial septum without any vegetations on the 
percutaneous device until today. She has had no further thromboembolic events.
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INTRODUCTION
Ischemic stroke is associated with multiple etiologies and 
diverse pathogenic mechanisms. Despite numerous studies 
suggesting a relationship between paradoxical embolism 
from a patent foramen ovale (PFO) and cerebrovascular 
accidents, the role of a PFO as a risk factor for cerebral 
ischemia remains controversial.[1] Otherwise it is well known 
that coagulation disorders like sticky platelet syndrome 
(SPS) are also common in young patients with ischemic 
stroke.
SPS is a congenital disorder characterized by platelet 
hyperaggregability to epinephrine and/or adenosine 
diphosphate (ADP), thus increasing the risk of acute 
myocardial infarction, ischemic optic neuropathy, recurrent 
venous thromboembolism, and transient ischemic cerebral 
attacks and strokes.[2] In this paper, we report a case of 
successful treatment of recurrent strokes due to SPS in 
a patient with a PFO that was managed by transcatheter 
closure and anticoagulation with low-dose acetylsalicylic 
acid. 
CASE REPORT
This report describes a 56-year-old female patient with a 
PFO who suffered from recurrent strokes despite long-
term medication with clopidogrel for SPS. In 1997, the 
patient was diagnosed with a transient ischemic attack 
(TIA) with initial right-sided hemihypesthesia followed by 
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discrete, accented brachiofacial hemiparesis. After 20 h, 
all symptoms resolved. Cardiovascular and neurological 
examinations were unremarkable. The patient was 
discharged without any residual defects.
In December 2007, the patient was admitted because 
of acute sensomotoric aphasia as well as a right-sided 
discrete, distinctive, accented brachiofacial hemiparesis. 
Magnetic resonance imaging (MRI) of the brain was 
performed and she was diagnosed with an ischemic stroke. 
The cardiovascular examination was unremarkable. After 
thrombolytic, occupational, and speech therapy, the patient 
was discharged without complaints. 
In view of the suspected allergy to acetylsalicylic acid, a 
permanent anticoagulant with clopidogrel was prescribed 
(75 mg daily). 
Despite the long-term anticoagulant treatment with 
clopidogrel, the patient was admitted again in December 
2008 with global aphasia. While exercising, she suddenly 
felt nauseated and dizzy, and had speech difficulty. 
During admittance, the patient was well oriented and 
cardiopulmonary stable, however, not able to communicate 
verbally or in writing. Motoricity, sensibility, and word 
understanding seemed to be well conserved. Demand 
or requests were followed up promptly. Immediate 
investigations revealed an ischemic cerebrovascular accident 
in the area of the media cerebral arterial distribution. A 
systemic thrombolytic therapy was prescribed which 
resulted in regression of symptoms. However, during 
this admission, transthoracic and transesophageal 
echocardiogram revealed a PFO. She was treated with 
intravenous heparin and later prescribed warfarin. The 
patient recovered without any residual defects and was 
discharged in a fortnight with continued rehabilitative 
therapy. Three months later, the anticoagulation regime 
was changed from clopidogrel to subcutaneous heparin 
and a series of hypercoagulability studies was performed. 
The results were positive for SPS type II. As a result, 
the anticoagulant treatment was adjusted to include 
low-dose acetylsalicylic acid (100 mg/day). The analysis 
at 1 month demonstrated a therapeutic effect of the 
low-dose acetylsalicylic acid medication. In addition, the 
closure of the PFO was performed under transesophageal 
echocardiography control at a specialised center in April 
2009. After percutaneous closure, the patient received 
clopidogrel (75 mg/day for 6 months) additionally. The 
postoperative course was unremarkable and the patient 
was discharged after 5 days. An intact atrial septum with a 
correct positioning of the implanted device was seen in the 
18-month follow up. She has since had thrombotic events, 
is free of pain, and able to do well in activities of daily living. 
Patient’s children were also evaluated for hypercoagulable 
states, although neither reported a previous thrombotic 
event. The daughter showed heterozygosity for  SPS and 
both sons had no coagulation disorders.
DISCUSSION
The cause of stroke remains unknown in roughly one-third 
of patients, despite extensive investigation. The presence 
of a PFO, a remnant of the fetal circulation that is present 
in approximately 25% of the general population, has been 
linked to an increased risk of ischemic stroke, especially in 
cases without an alternative explanation (cryptogenic strokes).
[3-5] And it is well known that recurrent thromboembolic 
events are more frequent in patients who have had a PFO 
associated with paradoxical embolism.[6,7] Otherwise, 
inherited hypercoagulable states like deficiencies of specific 
coagulation inhibitors or platelet hyperactivity can also result 
in thromboembolic events. 
Hyperactivity of platelets was found in SPS and was first 
described in 1983.[8] SPS appears to be transmitted with 
an autosomal pattern and about two-thirds of the affected 
patients have a positive family history of thromboembolic 
disease. 
It has been noted in previous studies that an increased 
sympathetic activity associated with emotional stress results 
in a higher level of epinephrine, which is accompanied by an 
increased platelet reactivity with unexplained arterial and/or 
venous thrombotic events.[9]
SPS was identified as a cause of thromboembolic kidney graft 
infarction,[10] arterial microemboli in the fingers,[11] peripheral 
arterial occlusion,[12] and stroke.[13] Treatment of SPS is 
acetylsalicylic acid medication, as it inhibits platelet aggregation 
and prevents recurrent thromboses [14].
In our case, the etiology of patient’s neurological events is 
more than difficult to explain. The PFO or SPS might have 
caused the recurrent strokes. A second possibility, which might 
be especially important in our case, is the combination of SPS 
and PFO which further increases the recurrent strokes than 
either etiology alone.
Due to this, the decision to treat PFO was made. However, 
to date, there is a considerable uncertainty about the 
optimal management of patients with PFO and stroke, with 
treatment strategies including systemic anticoagulation,[15] 
open-heart surgery,[16-18] and transcatheter PFO closure[19,20] 
having been proposed to reduce the risk of recurrent 
events. 70 Journal of Cardiovascular Disease Research Vol. 2 / No 1
Gehoff et al.: Sticky platelet syndrome with recurrent strokes
The patient was informed of the options of treatment, 
and she decided to undergo percutaneous closure. We are 
convinced that the decision in this case was correct and 
safe, because the percutaneous closure of PFO is a safe 
procedure associated with a high success rate and a low 
incidence of periprocedural complications and recurrences 
of thromboembolic events.[20] 
We believe that SPS is a frequent disease predisposing to 
vascular events but often remains undiagnosed as long as 
no second insult to the coagulation system or vasculature 
occurs. In this case report, the third cerebrovascular 
accident in combination with the diagnosis of a PFO led 
to extended investigations of the hemostatic system. One 
should keep in mind that the therapy with warfarin, if the 
SPS were responsible for the recurrent strokes, was not 
adequate to prevent further vascular complications.
CONCLUSIONS
This case report highlights the importance of thorough 
investigations of the hemostatics system of patients 
who experience thrombotic events, especially under 
anticoagulation therapy. As demonstrated in this report, 
the combination of hemostatitic abnormality and a PFO 
is unique in the current stroke literature. 
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